REDWOOD CITY, Calif., June 20, 2017 (GLOBE NEWSWIRE) — Biotricity, Inc. (BTCY), a medical diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions, today announced it has received ethics approval to conduct a study that will investigate and validate a mobile wireless fetal heart rate variability (HRV) monitor. Achieving ethics approval to conduct a clinical investigation is a significant accomplishment as the responsible institution must review the entire project from design, methodology, risk, goals, and other factors before proceeding.
The study will be conducted at Rockyview General Hospital by Dr. David Liepert, the Director of Quality Assurance and Improvement for Department of Anesthesia, and Dr. Reed Ferber an Associate Professor in the Faculty of Kinesiology and the Director and Chief Scientific Officer of the Running Injury Clinic. Both are accomplished professionals and members of Biotricity’s scientific and medical advisory board. Dr. Reed is a world-recognized expert in sensors and signal processing, and Dr. Liepert’s work with wearable technology, clinical medicine and patient safety will be invaluable as the Company investigates the pre-natal monitoring sphere.
About the Study:
Early and consistent prenatal care improves the chances of a healthy pregnancy for both mother and child. Prenatal monitoring helps physicians and other caregivers to better control existing conditions in the mother, such as high blood pressure and diabetes, and help avoid serious complications in pregnancy from other disorders, such as preeclampsia. Regular monitoring reduces the infant’s risk for complications as well, making unforeseeable risks more predictable, manageable and potentially preventable.
Mobile, wearable systems for fetal ECG recording will allow for real-time and real-life evaluation of both the baby’s and mother’s status. An electrical sensing ECG monitor provides a higher sampling rate than conventional techniques. This allows for a higher level of heart rate variability processing and automation, which can help differentiate artifacts from the heart rates of both the mother and the baby. This enhanced accuracy could further help save lives and improve the overall quality of prenatal care.
“Estimating the heart rate variability pre-birth is a natural progression for Biotricity, whose main goal in this sphere is to research future medical devices that are easy to implement in both the physician’s office and the patient’s home, that are comfortable and small, and that can offer precise remote data and care,” said Waqaas Al-Siddiq, Founder and CEO of Biotricity. “We are extremely excited to receive ethics approval and look forward to building on the research of our flagship product, Bioflux, which is a highly accurate, clinical-grade remote patient monitoring device that specifically focuses on individuals diagnosed with or at risk for cardiovascular disease.”
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com or follow on Twitter: @biotricity_inc Facebook facebook.com/biotricity/ or LinkedIn linkedin.com/company/biotricity-measuring-vitals
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development, regulatory approvals and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
CONTACT: Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, firstname.lastname@example.org, 978-433-3304 Investor Relations: Liolios Group, Inc. BTCY@liolios.com, 949-574-3860